Lv1
100 积分 2024-09-19 加入
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
6个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
7个月前
已完结
Telisotuzumab Vedotin: First Approval
9个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
10个月前
已完结
皖公网安备34019202002308
